<DOC>
	<DOCNO>NCT03041363</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) , percentage calorie consume , triheptanoin ( C7 oil ; C7 ) pediatric adult patient population genetically diagnose glucose transporter type 1 deficiency disorder ( G1D ) .</brief_summary>
	<brief_title>Treatment Development Triheptanoin ( G1D )</brief_title>
	<detailed_description>The trial use open-label , standard 3+3 phase design determine MTD orally-administered C7 G1D . Triheptanoin : triglyceride oil contain three odd-carbon chain-length fatty acid ( i.e. , triglyceride 7-carbon heptanoic acid ) . Triheptanoin take 4 time per day ( approximately every 6 hour ) mouth . dose 4 time per day , divide evenly , total C7 daily dose re-place 40 % 45 % ( depend group ) daily caloric intake fat usual diet , base current protocol guideline . The oil take approximately one hour meal , mixed fat-free , sugar-free yogurt pudding administration . Up thirty-six subject enrol 10-day maximum tolerable dose trial C7 . initiation C7 dosing conduct Children 's Medical Center Dallas ambulatory Care Pavilion neurology Clinic . Sub-jects provide C7 oil take 7 day administration . Subjects require stop medication . Subjects di-rected maintain usual medication , include rescue seizure medication , necessary course study . Subjects may clinical medical record transfer back refer physician completion study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Carbohydrate Metabolism , Inborn Errors</mesh_term>
	<criteria>Diagnosis glucose transporter type I deficiency ( G1D ) confirm genotyping PET scan brain . Stable dietary therapy ( i.e. , dietary therapy 1 month , include , limited , medium chain triglyceride therapy ) . Males females 2 year 6 month 17 year 11 month old , inclusive . Subjects history lifethreatening seizure episode , include limited status epilepticus cardiac arrest . Subjects evidence independent , unrelated metabolic and/or genetic disease . Subjects body mass index ( BMI ) great equal 30 . Subjects chronic gastrointestinal disorder , irritable bowel syndrome , Crohn 's disease , colitis , could increase subject 's risk develop diarrhea stomach pain . Subjects currently dietary therapy ( i.e. , ketogenic diet , medium chain triglyceridesupplemented diet , Atkins diet version , low glycemic index diet , related diet ) . Women pregnant breastfeeding may participate . Women plan become pregnant course study , unwilling use birth control prevent pregnancy ( include abstinence ) may participate . Females age 10 ask provide urine sample pregnancy test via dipstick . Subjects ask agree abstinence another form birth control duration study . Allergy/sensitivity C7 . Previous treatment C7 one month prior enrollment . Treatment medium chain triglyceride last 30 day . Subjects exhibit sign dementia , diagnose degenerative brain disorder ( Alzheimer 's disease ) would confound assessment cognitive change , opinion investigator . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Inability unwillingness 2 parent legal guardians/representatives give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>